Proteomics International Laboratories Ltd. (PIQ) Price & Analysis

Compare

32 Followers

PIQ Stock Chart & Stats

AU$0.67

AU$0.03(4.23%)

At close: Jan 09 4:00 PM EST

AU$0.67

AU$0.03(4.23%)

Day’s Range― - ―

52-Week RangeAU$0.29 - AU$0.86

Previous CloseN/A

Volume90.30K

Average Volume (3M)426.90K

Market Cap

AU$80.94M

Enterprise ValueAU$70.18M

Total Cash (Recent Filing)AU$11.04M

Total Debt (Recent Filing)AU$277.74K

Price to Earnings (P/E)―

Beta1.56

Next Earnings

Mar 04, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding165,184,000

10 Day Avg. Volume295,611

30 Day Avg. Volume426,904

Financial Highlights & Ratios

PEG Ratio-0.84

Price to Book (P/B)3.69

Price to Sales (P/S)50.61

P/FCF Ratio-7.33

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.43

Price Target Upside-35.82% Downside

Rating ConsensusModerate Sell

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Balance Sheet StrengthA very low debt-to-equity ratio provides durable financial flexibility, lowering insolvency risk and preserving capacity to fund R&D, regulatory work, or strategic partnerships without heavy interest burdens. This supports survival through biotech cycles and future investment.

Positive Gross Profitability On Core ServicesPositive gross margins indicate the company’s core proteomics and diagnostic services are economically viable. If fixed operating costs are controlled, scalable service delivery and higher utilization can translate this into lasting operating profitability over months as revenue stabilizes.

Strategic Positioning In Proteomics And Personalized MedicineSpecialization in proteomics and personalized medicine targets a structural growth area in healthcare. Recurring contract research, diagnostic testing and academic partnerships create durable demand channels and potential licensing pathways that can support sustainable revenue over time.

Bears Say

Steep Revenue DeclineA large year-over-year revenue contraction materially reduces economies of scale and pricing leverage. Persistently lower top-line volume undermines investment returns on proprietary platforms, strains customer relationships, and increases reliance on non-operating funding sources.

Persistent Operating Losses And Negative MarginsOngoing negative EBIT and net margins show core operations do not cover operating expenses. Over the medium term this limits reinvestment capacity, risks dilution if capital is raised, and requires either sustained margin improvement or external funding to achieve profitability.

Negative Operating And Free Cash FlowConsistent negative operating and free cash flow erodes cash reserves and forces reliance on financing or equity raises. This constrains the company’s ability to fund commercialization, clinical validation, or scaling efforts, posing a structural liquidity risk in coming months.

Proteomics International Laboratories Ltd. News

Proteomics International Seeks ASX Quotation for Additional 67,566 Shares

Proteomics International Laboratories Ltd. ( ($AU:PIQ) ) just unveiled an announcement. Proteomics International Laboratories Ltd has applied to...

3d ago

PIQ

Proteomics International Seeks ASX Quotation for 1.16m New Shares

The latest announcement is out from Proteomics International Laboratories Ltd. ( ($AU:PIQ) ). Proteomics International Laboratories Ltd has...

15d ago

PIQ

Proteomics International Appoints David Morris to Board With No Initial Shareholding

Proteomics International Laboratories Ltd. ( ($AU:PIQ) ) has issued an announcement. Proteomics International Laboratories Ltd has appointed David...

17d ago

PIQ

Proteomics International Wins Canadian Patent for PromarkerEso Esophageal Cancer Test

Proteomics International Laboratories Ltd. ( ($AU:PIQ) ) just unveiled an update. Proteomics International Laboratories has secured a Canadian...

21d ago

PIQ

Proteomics International Seeks ASX Quotation for 147,286 New Shares

Proteomics International Laboratories Ltd. ( ($AU:PIQ) ) has issued an update. Proteomics International Laboratories Ltd has applied to...

21d ago

PIQ

Proteomics International Names David Morris CEO to Lead Global Commercial Push

Proteomics International Laboratories Ltd. ( ($AU:PIQ) ) has provided an update. Proteomics International Laboratories has appointed David Morris...

22d ago

PIQ

Proteomics International Seeks ASX Quotation for Additional 32,430 Shares

An announcement from Proteomics International Laboratories Ltd. ( ($AU:PIQ) ) is now available. Proteomics International Laboratories Ltd has...

24d ago

PIQ

Proteomics International Announces Lapse of 15,072 Employee Performance Rights

Proteomics International Laboratories Ltd. ( ($AU:PIQ) ) just unveiled an announcement. Proteomics International Laboratories Ltd has notified the...

27d ago

PIQ

Proteomics International Wins CAP Accreditation, Commissions US Mass Spec Lab for Promarker Tests

Proteomics International Laboratories Ltd. ( ($AU:PIQ) ) just unveiled an announcement. Proteomics International Laboratories has strengthened its US...

1M ago

PIQ

PromarkerD Test Enhances Diabetic Kidney Disease Management in Australia

The latest announcement is out from Proteomics International Laboratories Ltd. ( ($AU:PIQ) ). Proteomics International Laboratories Ltd announced...

2M ago

PIQ

PIQ FAQ

What was Proteomics International Laboratories Ltd.’s price range in the past 12 months?

Proteomics International Laboratories Ltd. lowest share price was AU$0.28 and its highest was AU$0.86 in the past 12 months.

What is Proteomics International Laboratories Ltd.’s market cap?

Proteomics International Laboratories Ltd.’s market cap is AU$80.94M.

When is Proteomics International Laboratories Ltd.’s upcoming earnings report date?

Proteomics International Laboratories Ltd.’s upcoming earnings report date is Mar 04, 2026 which is in 27 days.

How were Proteomics International Laboratories Ltd.’s earnings last quarter?

Proteomics International Laboratories Ltd. released its earnings results on Aug 26, 2025. The company reported -AU$0.026 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.026.

Is Proteomics International Laboratories Ltd. overvalued?

According to Wall Street analysts Proteomics International Laboratories Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Proteomics International Laboratories Ltd. pay dividends?

Proteomics International Laboratories Ltd. does not currently pay dividends.

What is Proteomics International Laboratories Ltd.’s EPS estimate?

Proteomics International Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Proteomics International Laboratories Ltd. have?

Proteomics International Laboratories Ltd. has 165,184,000 shares outstanding.

What happened to Proteomics International Laboratories Ltd.’s price movement after its last earnings report?

Proteomics International Laboratories Ltd. reported an EPS of -AU$0.026 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Proteomics International Laboratories Ltd.?

Currently, no hedge funds are holding shares in AU:PIQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Proteomics International Laboratories Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-71.87%

Trailing 12-Months

Asset Growth

35.92%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Proteomics International Laboratories Ltd.

Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute and the Janssen Research & Development for the research of diabetic kidney disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma. The company was founded in 2001 and is based in Perth, Australia.

Proteomics International Laboratories Ltd. (PIQ) Earnings & Revenues

Historic Earnings Reports

PIQ Stock 12 Month Forecast

Average Price Target

AU$0.43

▼(-35.82% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.43</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Jul<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.505,0.49923076923076926,0.49346153846153845,0.4876923076923077,0.4819230769230769,0.47615384615384615,0.4703846153846154,0.4646153846153846,0.45884615384615385,0.45307692307692304,0.4473076923076923,0.44153846153846155,0.43576923076923074,{"y":0.43,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.505,0.49923076923076926,0.49346153846153845,0.4876923076923077,0.4819230769230769,0.47615384615384615,0.4703846153846154,0.4646153846153846,0.45884615384615385,0.45307692307692304,0.4473076923076923,0.44153846153846155,0.43576923076923074,{"y":0.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.505,0.49923076923076926,0.49346153846153845,0.4876923076923077,0.4819230769230769,0.47615384615384615,0.4703846153846154,0.4646153846153846,0.45884615384615385,0.45307692307692304,0.4473076923076923,0.44153846153846155,0.43576923076923074,{"y":0.43,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.86,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.86,"date":1669852800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.79,"date":1725148800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.48,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.42,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.36,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.4,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 52, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.505,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >